BASF expands solubilisation and dermatology excipients portfolio

Resulting from Cognis acquisition in 2011

BASF has significantly expanded its range of solubilisation and dermatology excipients following the acquisition of Cognis in 2011.

The new products, launched this month, include pharmaceutical-grade solubilisers, emulsifiers, solvents, consistency factors and emollients for all dosage forms.

BASF has developed a new naming system for these products, enabling customers easily to identify each excipient’s application.

All products within these portfolios now have ‘Kolli’ as the stem, plus a suffix reflecting the chemical structure: ‘phor’ for solubilisers and emulsifiers, ‘solv’ for solvents, ‘wax’ for consistency factors, and ‘cream’ for emollients.

‘The new naming structure ensures a consistent branding for all products compliant with pharmaceutical regulations and to better facilitate customer orientation through strong and clear branding and clustering,’ explained Thomas Rosen, head of Global Marketing Dermatology & Solubilisation.

BASF’s recently published Solubilisation Compendium provides expert advice on solubilising compounds with poor solubility and bioavailability profiles. The publication provides an overview of all relevant BASF excipients, and offers guidance on selecting the most suitable product. In addition, it features chapters on the basic principles of solubilisation, and offers practical advice on creating solid solutions and dispersions.

Companies